ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

ADMA Biologics, Inc.NASDAQ: ADMA

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to 30.4%

Net margin was 30.4% in Q2 FY2026, up 2.4 pp from a year earlier. On a trailing-twelve-month basis it was 33.0%, down 11.1 pp year over year. Over 3 fiscal years it widened by 71.6 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of 37.7% for the fiscal year ending Dec 2026, up from 28.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
30.4%-9.2 pp QoQ
Last fiscal yearDec 2025
28.8%-17.6 pp YoY
LTMJun 2026
33.0%-11.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.4 pp+5.0 pp+2.7 pp
1 year-17.6 pp+8.9 pp+26.4 pp
3 years+71.6 pp+10.1 pp-61.5 pp
5 years+15.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
28.8%
Year-over-year change
-17.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ADMA compares with its peers on the latest reported figures

  • ADMA's LTM Jun 2026 net margin of 33.0% is the 2nd highest of the 4 companies compared; the peer median is 6.1%.
  • Its year-over-year change of -11.1 pp is the lowest of 4, against a peer median of +250.1 pp.
  • Over three fiscal years its change of +71.6 pp compares with a peer median of -28.8 pp.
ADMA Competitors Peer median
Net Margin for ADMA and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 202684.0% +1279.8 pp-59.9 pp
ADMAADMA Biologics, Inc.LTM Jun 202633.0% -11.1 pp+71.6 pp
GRFSGrifols, S.A.LTM Jun 20266.1% +2.1 pp+2.3 pp
IVVDInvivyd, Inc.LTM Mar 2026-138.9% +250.1 pp—
Peer median (excluding ADMA) 6.1%+250.1 pp-28.8 pp

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.